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Abstract. A simple method of using compactin for effective screening of microbial strains with high
hydroxylation activity at the 6b position of compactin was developed. Agar plates containing different
carbon sources and 500 lg compactin mL)1 were used to screen the microorganisms that can convert
compactin to pravastatin. About 100 compactin-resistant strains were isolated from the Basal agar
containing 7% (w/v) mannitol as a carbon source, in which two bacteria, Pseudomocardia auto-
trophica BCRC 12444 and Streptomyces griseolus BCRC 13677, capable of converting compactin to
pravastatin with the yield of 20 and 32% (w/w), respectively, were found. High-performance liquid
chromatography using C-18 column and two sequential mobile phases, 30% and 50% (v/v) aceto-
nitrile, was also established to simultaneously determine the concentration of compactin and prava-
statin in the culture broth. As such, about 2% of target microorganisms could be obtained from the
screening program.
Statin drugs are currently the most therapeutically
effective drugs to reduce the level of low-density lipo-
protein in the bloodstream of a patient at risk for car-
diovascular disease. The statin drugs disrupt the
synthesis of cholesterol by competitively inhibiting the
activity of 3-hydroxy-3-methyl-glutaryl-coenzyme A
reductase [2]. Among the statin drugs, pravastatin
exhibits an important therapeutic advantage, i.e., it
selectively inhibits cholesterol synthesis in the liver and
small intestine but leaves cholesterol synthesis in the
peripheral cells substantially unaffected [12, 14].
In the early days of its development as a statin
drug, pravastatin was obtained from compactin by
means of chemical synthesis [7], but more recently,
due to problems of high cost and the occurrence of
stereoisomers, the most economically feasible method
of making pravastatin is by enzymatic hydroxylation of
compactin at the C-6 position. Compactin is produced
by the fermentation of Penicillium citrinum [4, 5].
However, microorganisms seldom are found to have a
potent hydroxylating ability on compactin at the 6b-
position. Streptomyces carbophilus is one of the most
effective microorganisms, which has shown the
hydroxylation activity performed by a cytochrome
P450 system [6]. Actinomadura sp. strain 2966 appears
to have another cytochrome P450 system in the con-
version of compactin to pravastatin [8]. Although some
microorganisms have the ability to convert compactin,
the resulting products other than pravastatin, such as
3a- and 3b-hydroxycompactin, are found in the
hydroxylation of compactin by Syncephalastrum
nigricans and Mucor hiemalis [9].
Microorganisms sensitive to compactin are one of
the problems in the production of pravastatin. A high
concentration of compactin in the culture broth not only
inhibits the cell growth but also causes cell lysis during
the conversion of compactin to pravastatin [5, 7].
Therefore, establishment of a simple and rapid method
for the screening of compactin-resistant strains with the
capability of converting compactin to pravastatin is
performed in this study.Correspondence to: Hui-Yu Hu; email: huiyu@sunrise.hk.edu.tw
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Materials and Methods
Microorganisms, chemicals, and culture media. Microorganisms
were isolated from soils in the National Chung Hsing University
(Taichung, Taiwan) and from wastewater in the petroleum plant of
Chinese Petroleum Co. (Taipei, Taiwan), and obtained from the
Bioresources Collection and Research Center (BCRC, Hsinchu,
Taiwan). Soil was put through a 5-mm sieve to remove roots and
large particulates and stored at 4C until use. Bacteria were identified
by 16S rRNA gene sequence alignment and biological
characterization. For 16S rRNA gene sequencing, the genomic DNA
was extracted from the cells and 16S rRNA gene was amplified by
PCR using primers fD1 (5¢-AGAGTTTGATCCTGGCTCAG-3¢) and
rD1 (5¢-AAGGAGGTGATCCAGCC-3¢) [15]. PCR amplification was
performed using a Thermocycler model 9600 (Perkin-Elmer, Norwalk,
CT, USA). DNA was amplified for 25 cycles of denaturation at 94C
for 1.5 min, annealing at 65C for 2 min, and elongation at 72C for 2
min. The final extension step at 72C for 5 min was included. The PCR
product was purified and then ligated into pGEM-T Easy vector
(Promega Co., Madison, WI, USA). The nucleotide sequences were
determined by Protech (Taipei, Taiwan). The obtained sequences were
compared to those in the National Center for Biotechnology
Information nucleotide sequence database by using the BLAST
algorithm [1]. The biological characteristics and cellular fatty acids
composition of the strain were performed by BCRC (Taiwan).
Compactin and pravastatin were purchased from Standard Chem. &
Pharm. Co. (Tainan, Taiwan). Basal medium [1% (w/v) yeast extract,
0.15% (w/v) soy meal, 0.05% (w/v) polyethyleneglycol, 0.1% (w/v)
KH2PO4, and 0.1% (w/v) KCl; pH 7.0] containing 7% (w/v) of
mannitol, glycerol, glucose, or lactose was used for the isolation and
cultivation of compactin-resistant strains.
Screening of pravastatin-producing strains. Enrichment of
microorganisms transforming compactin was performed with 1%
inocula from both the soils and wastewater using Basal medium
containing different carbon sources and 100 lg compactin mL)1. The
cultures were grown at 28C with rotary shaking (220 rpm). After three
successive transfers (with a 1:10 dilution in every transfer), the
enrichment cultures obtained from the soils and wastewater were used
for the isolation of pure cultures. Pure culture with a similar
morphology was obtained in Basal agar incubated at 28C. A single
colony from enrichment cultures and BCRC strains was picked and
inoculated to different Basal agar plates containing 7% (w/v) of
various carbon sources and different concentrations of compactin in the
range of 0.1 to 1 mg mL)1 and incubated at 28C for 3 to 10 days. To
determine the hydroxylation activity of isolated microorganisms
toward compactin, colonies of compactin-resistant strains were
transferred from agar plates into a 100-mL Erlenmeyer flask
containing 20 mL of the Basal medium with 7% (w/v) of different
carbon sources and incubated at 28C for 2 days on a rotary shaker
(220 rpm). Five milliliters of the seed culture were inoculated into 100
mL of the Basal media containing 7% (w/v) of different carbon
sources. After incubating at 28C for 2 days, 500 lg compactin mL)1
were added into the culture broth to observe the conversion of
compactin to pravastatin.
HPLC analysis. Concentrations of compactin and pravastatin in
culture broth were analyzed by the HPLC method. The HPLC system
was a 625 LC System equipped with 717 plus Autosampler and 996
Photodiode Array Detector (Waters, Milford, MA). A VERCOPAK-
C18 column (3.2 · 250 mm, Vercotech, Taipei, Taiwan) was used and
UV detection was set at 235.9 nm for compactin and pravastatin. The
column was eluted with 30% (v/v) acetonitrile and 10% (v/v) methanol
for 20 min; or 30% (v/v) acetonitrile for 15 min, followed by 50% (v/v)
acetonitrile for 25 min. Elution was performed at room temperature
and a velocity of 1 mL min)1. Pravastatin from Standard Chem. &
Pharm. Co. was used as an internal standard.
Results and Discussion
Only a few microorganisms have been found to have the
capability to hydroxylate compactin at the 6b position
[13]. Moreover, the most effective microorganisms for
this type of hydroxylation suffer from a low tolerance to
a high concentration of compactin and produce a large
amount of byproducts [13]. It is, therefore, necessary to
establish an effective method to maximize the rate of
isolating microorganisms with the ability to convert
compactin to pravastatin. To enhance the rate of iso-
lating pravastatin producers, compactin was used as a
selective pressure to minimize the growth of undesired
candidates. In the preliminary screening of microor-
ganisms capable of converting compactin to pravastatin,
microorganisms from enrichment cultures and BCRC
were plated on the agar plate containing 7% (w/v) of
different carbon sources and 0.1 to 1 mg compactin
mL)1. Numerous colonies were found from the plates
supplemented with compactin less than 250 lg mL)1,
whereas no colony was found in the agar plate con-
taining 1 mg compactin mL)1. Therefore, Basal agar
plates containing 500 lg compactin mL)1 were used for
the screening of compactin-resistant strains. About 1000
compactin-resistant strains were obtained from various
sources, in which about 100 strains were isolated from
the Basal agar plate containing 7% (w/v) mannitol as a
carbon source.
Several approaches have been reported for the
detection of compactin and pravastatin, including mass
spectrometry, nuclear magnetic resonance, and infrared
spectroscopy [10]. However, the tedious assay proce-
Table 1. Bioconversion of compactin by compactin-resistant micro-
organisms
Microorganism
Residual
compaction in
culture broth (%)
Streptomyces regensis BCRC 11890 88
Pseudonocardia autotrophica BCRC 12444 80
Streptomyces griseolus BCRC 13677 68
Mucor hiemalis BCRC 32824 85
Rhodosporidium fluviale BCRC 22986 29
Xanthomonas compestries NCHU 1126 90
Amycalatopsis sulphurea NCHU 1345 90
Bacillus megaterium NCHU 1546 25
Salmonella enterica NCHU 1586 45
Cells were cultivated in Basal medium containing 500 lg compactin
mL)1 at 28C for 10 days.
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dures limit their practical application. The HPLC
method is frequently used to determine the concentra-
tion of pravastatin and its derivatives in human plasma
and urine [3] and in culture broth [11]. To observe the
transformation of compactin, compactin-resistant strains
were cultivated in the Basal media containing different
carbon sources at 28C for 2 days and then allowed to
grow for 10 days in the same medium containing
compactin. It was observed that cell lysis of isolated
microorganisms occurs in the culture broth containing
compactin at a concentration higher than that for our
screening program. Therefore, the concentration of 500
lg compactin mL)1 in Basal medium was chosen for
microbial hydroxylation. Nine strains with the potential
to convert compactin were identified by the HPLC
method using a mobile phase of 30% (v/v) acetonitrile
and 10% (v/v) methanol (Table 1). Among them, Sal-
monella enterica NCHU 1586, Streptomyces regensis
BCRC 11890, M. hiemalis BCRC 32824, Xanthomonas
compestries NCHU 1126, Amycalatopsis sulphurea
NCHU1345, Bacillus megaterium NCHU 1546, and
Rhodosporidium fluviale BCRC 22986 (Fig. 1A)
showed peaks with retention time around 7.4 min. The
other two strains, Pseudonocardia autotrophica BCRC
12444 (Fig. 1B) and Streptomyces griseolus BCRC
13677 isolated from the Basal agar plate containing 7%
(w/v) mannitol, had peaks with a retention time that
coincided with that of the internal standard, pravastatin
(7.5 min), on the chromatograms. The data revealed that
the transformed products from P. autotrophica BCRC
12444 and S. griseolus BCRC 13677 might be prava-
statin, and the compounds involved in this catalysis
could not be resolved clearly by the above HPLC
method.
Although these nine organisms can convert the
compactin to the products with a retention time close to
that of pravastatin, it is necessary to verify if the prod-
ucts are pravastatin. In order to achieve observable
chromatographic separation, two separation elutions
with different concentrations of acetonitrile were inves-
tigated. We found the HPLC method using 30% (v/v)
acetonitrile for 15 min followed by 50% (v/v) acetoni-
trile for 25 min could clearly separate pravastatin and
compactin (substrate) with retention times of 11.5 and
32 min, respectively (Fig. 2). The results suggested that
sequential use of two different mobile phases resulted in
a satisfactory resolution of compactin and pravastatin in
the culture broth.
To determine the ability of P. autotrophica BCRC
12444 and S. griseolus BCRC 13677 in the conversion of
compactin to pravastatin, cells were cultivated in the
different Basal media containing 500 lg compactin mL)1
at 28C. A low yield (<5%, w/w) was found for the cells
cultivated in the Basal media containing glucose, glyc-
erol, or lactose as a carbon source, whereas about 20% and
32% (w/w) of compactin were stoichiometrically con-
verted to pravastatin without a detectable byproduct by
P. autotrophica BCRC 12444 and S. griseolus BCRC
13677, respectively, in a 9-day incubation in the Basal
medium containing mannitol as a carbon source (Fig. 3).
The data showed thatmannitolmay serve as a good carbon
source for the cells involved in the conversion of comp-
actin to pravastatin. Although S. griseolus BCRC 13677
had a higher conversion ability, pravastatin rapidly de-
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Fig. 1. HPLC analysis of the products converted
from compactin by R. fluviale BCRC 22986 (A) and
P. autotrophica BCRC 12444 (B) using the mobile
phase of 30% acetonitrile and 10% methanol. a,
without internal standard (pravastatin); b, with internal
standard; PP, putative pravastatin.
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creased after a 10-day incubation, demonstrating that
pravastatin could be further converted to other products
by the cells.
D-Trehalose medium has been used in an extensive
screening program to discover microorganisms having
strong hydroxylation activity at the 6b position of
compactin. A potent converter, Streptomyces carbophi-
lus, which produces only limited byproducts, has been
found [13]. In this approach, target microorganisms
were obtained at the rate of about 2% from the enrich-
ment cultures, indicating that Basal medium containing
7% (w/v) mannitol and 500 lg compactin mL)1 in
combination with our HPLC method could be used for
the effective screening of the microorganisms with the
ability to convert compactin to pravastatin. Although the
maximal yield of pravastatin from compactin by isolated
microorganisms reached only 32%, no detectable by-
product was found in the 9-day incubation. Molecular
cloning of genes involved in the cytochrome P450
monooxygenase system from S. griseolus BCRC 13677
and P. autotrophica BCRC 12444 into a bacteria strain
with a high tolerance to compactin is currently in pro-
gress to develop a high-efficiency biotransformation
system for use in the drug industry.
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